FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, in particular to a method for preventing and / or reducing the severity of sepsis associated with S. aureus, and to a method for preventing and / or reducing the severity of pneumonia associated with S. aureus in immunocompromised patients using anti-S. aureus alpha toxin antibodies. Also provided is a method for reducing the bacterial load of S. aureus in the bloodstream or heart of a mammalian subject, comprising administering to the subject an effective amount of an isolated anti-S. aureus alpha toxin antibody or an antigen-binding fragment thereof. Also provided is a method for reducing the agglutination of S. aureus bacteria and / or forming thromboembolic lesion sites in a mammalian subject, comprising administering to the subject an effective amount of an isolated anti-S. aureus alpha toxin antibody or an antigen-binding fragment thereof.
EFFECT: anti-S. aureus alpha toxin antibodies are effective in the prevention of sepsis and pneumonia in individuals with weakened immunity.
30 cl, 7 dwg, 11 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES FOR SPECIFIC BINDING OF STAPHYLOCOCCUS AUREUS ALPHA-TOXIN AND METHODS OF APPLICATION | 2012 |
|
RU2620065C2 |
| ANTIBODIES TO SURFACE DETERMINANTS OF S. AUREUS | 2013 |
|
RU2808018C2 |
| ANTIBODIES TO S. AUREUS SURFACE DETERMINANTS | 2013 |
|
RU2698131C2 |
| COMBINATIONS OF ANTIBODIES TO STAPHYLOCOCCUS AUREUS | 2019 |
|
RU2804815C2 |
| STAPHYLOCOCCUS AUREUS CLUMPING FACTOR A (ClfA) ANTIBODY | 2019 |
|
RU2818805C2 |
| HUMANIZED ANTI-C5 ANTIBODIES AND THEIR APPLICATION | 2019 |
|
RU2792237C2 |
| ANTIBODIES AGAINST STAPHYLOCOCCUS AUREUS LEUKOTOXINS | 2019 |
|
RU2805969C2 |
| ANTI-C5 ANTIBODIES AND THEIR USE | 2018 |
|
RU2774716C2 |
| ANTIBODIES TO CANINE INTERLEUKIN-4 ALPHA RECEPTOR | 2016 |
|
RU2736732C2 |
| ANTIBODIES OF DOGS WITH MODIFIED CH2-CH3 SEQUENCES | 2014 |
|
RU2687209C1 |
